- Home
- » e-Newsletters
FDA recalls injectable products from MD pharmacy
Pharmacy Regulation Resource, September 21, 2005
Concerned about sterility, the FDA on September 16 notified hospitals and healthcare professionals about a recall of all injectable products from a Maryland compounding pharmacy.
Tests identified gram negative rod bacteria in two lots of cardioplegia solution manufactured by Central Admixture Pharmacy Services Inc. of Lanham, MD, according to a product safety alert from the FDA. The FDA identified the following products distributed up to September 16 in the recall:
- Cardioplegia solutions including: cardioplegia, cold cardioplegia, warm cardioplegia, blood cardioplegia 1, blood cardioplegia 2, cardioplegia base 1, cardioplegia base 2, cardioplegia base, cardioplegia reperfusion, cardioplegia high potassium, cardioplegia low potassium, cardioplegia #1, cardioplegia #2, cardioplegia #3; maintenance cardioplegia, enriched cardioplegia, cardioplegia hot shot, cardioplegia base enriched
- Oxytocin injectable products including: oxytocin infusion, oxytocin 20 units, oytocin 30 units, oxytocin D5 ½ NS, oxytocin in lactated ringers
- Promethazine
- Magnesium-containing injectable products including: magnesium 1 GM, magnesium 2 GM, magnesium sulfate 2 GM, magnesium 4 GM, hydration-magnesium in D5W, magnesium infusion, magnesium in lactated ringers
- Heparin replacement
- Antibiotic irrigation bag and bottle
- Bupivicaine 0.25 % and 0.5%, pain bags (bupivicaine 0.25 %)
- Dialysate solutions including: citrate dialysate, heparin dialysate, pediatric dialysate, hydration dialysate #1, hydration dialysate #2, CRRT dialysate, CVVHD (dialysate) 300, CVVHD (dialysate) 342, CVVHD pediatric formula (Normocarb), CVVHD formalin #1, CVVHD formalin #2, CVVHD formalin #3, CVVHD non-standard, CVVHD D5W, CVVHD ½ NS, CVVHD NS
- Total parenteral nutrition (TPN) products including: TPN-Day, TPN-Day 1 Neonatal Stock Solution
- Diltiazem (Cardizem)
- Norepinephrine (Levophed)
- Cefazolin
The FDA urged hospitals and healthcare providers to identify in their stock any of those products from Central Admixture Pharmacy Services and discontinue their use.
For more on the recall, visit www.fda.gov/medwatch/safety/2005/safety05.htm#CAPS.
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- Capturing all necessary codes for IUD insertion and removal can be challenging
- QA:Coding multiple initial infusions
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- OB services: Coding inside and outside of the package
- HIPAA Q&A: Level of encryption needed for email
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- What does case-mix index mean to you?
- Q&A tackles coding questions about injections and infusions
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- HIPAA Q&A: Level of encryption needed for email
- Searched